. 2010 Nov 19;32(3):351–358. doi: 10.1093/carcin/bgq251

Table II.

Effect of Zn supplementation on the incidence of tumors in Fhit−/− mice

Treatment	Totalmice	Mice bearing tumors	Tumors per mouse (mean ± SE)	^aTumors of specific diameter per mouse
Treatment	Totalmice	Mice bearing tumors	Tumors per mouse (mean ± SE)	≤0.5 mm	0.5–2 mm	≥2 mm
No Zn	7	7 (100%)	8.00 ± 0.98	6.00	1.00	1.00
Zn1: Zn supplement starting after last NMBA dose	14	13 (92.6%)	3.14 ± 0.49^b	2.43^b	0.21	0.50
Zn7: Zn supplement starting 7 weeks after last NMBA dose	9	9 (100%)	3.67 ± 0.96^b	2.89^b	0.67	0.11^a

Mice were separated into three treatment groups: no Zn supplementation, Zn supplementation starting immediately (Zn1) or Zn supplementation begun 7 weeks after NMBA administration (Zn7). Mice were killed and esophagus, stomach, liver, kidney, spleen and intestine grossly examined at 14 weeks after final dose of NMBA. Tumors were found only in forestomach and were measured and enumerated. Statistical analyses showed significant differences between control and the two Zn-supplemented groups (P < 0.01). There was no significant difference between two Zn treatment groups.

Significantly lower than no Zn supplement group with P value ≤ 0.05.

Significantly lower than no Zn supplement group with P value ≤ 0.01.